Collagenase Clostridium Histolyticum (CCH)

DRUG3 trials

Sponsors

Endo Pharmaceuticals, University of Miami

Conditions

Edematous SkinGenital Diseases, MalePeyronie DiseasePlantar FasciitisSexual Dysfunctions, Psychological

Phase 2

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

CompletedNCT03632993

Endo PharmaceuticalsEdematous Skin

Start: 2018-09-18End: 2019-01-24Updated: 2023-09-07

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

CompletedNCT06169319

Endo PharmaceuticalsPlantar Fasciitis

Start: 2024-01-03End: 2024-09-30Updated: 2025-09-30

Phase 4

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

Active, not recruitingNCT05777031

University of MiamiGenital Diseases, Male, Peyronie Disease, Sexual Dysfunctions, Psychological

Start: 2023-10-02End: 2027-01-15Updated: 2026-06-04

Related Papers

A Phase 1, Single-Blind, Randomized, Placebo-Controlled Dose Escalation Study to Assess Collagenase Clostridium Histolyticum (CCH) vs Placebo in Patients With Plantar Fasciitis (PFA)

Foot & Ankle Orthopaedics2025-10-01